Ordering
How to Order
1. Order AccuCEA and/or Specimen Storage
- Download the requisition form for First-Line Testing or Storage
(NY Customers Click Here) - Include Patient Billing Demographic sheet and EUS report.
- Ship specimen using provided kit with frozen shipping blocks.
- Specimens will reside in storage at Interpace Diagnostics for up to 45 days.
2. Order PancraGEN Molecular testing when clinically appropriate.
- Download the Pancreatic Molecular Requisition for Second-Line Testing.
(NY Customers Click Here) - Include EUS report and cytology, CEA, and amylase reports (IF NOT tested by Interpace Diagnostics).
- Fax Requisition form and clinical reports to Interpace Diagnostics at
888-674-6894.
Turnaround Time
Expect a PancraGEN™ report delivered within 10 to 14 business days from the date of the requisition form (and sample, if applicable) submission.
Easy to Use
- With AccuCEA™ streamline your diagnostic practice with this highly specialized CEA assay for Pancreatic Cysts only requiring 200uL of fluid; reflex to PancraGEN molecular testing as needed.
- Comprehensive services including cytopathology, AccuCEA, storage, and molecular testing with a single sample (600ul).
- Results Reports that are easy to read, conveniently delivered through our online portal.
- Customer service and in-servicing for your office are available.
- Patient financial assistance available through our Compass program.
AccuCEA™
AccuCEA is our highly accurate CEA method designed specifically for pancreatic cyst fluids and is especially convenient when used with PancraGEN.
- The only CEA assay validated for use on small volumes (200uL) of cyst fluid.
- Delivers accurate CEA measurements on pancreatic cyst fluids
- Offers physicians more options – reserve cyst fluid for other diagnostic tests
- Results reported within 1-3 business days
- Al-Haddad MA, Kowalski T, Siddiqui A, et al. Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts. Endoscopy. 2015;47(2):136-146.
- V. Chernyak et al, Incidental pancreatic cystic lesions Radiology 2015 274 161-9
- BU Wu, et al, Prediction of malignancy in cystic neoplasms of the pancreas: a population based cohort study, Am J Gastro 2014 109 121-9
- Loren D, Kowalski T, Siddiqui A, et al. Influence of integrated molecular pathology test results on real-world management decisions for patients with pancreatic cysts: analysis of data from a national registry cohort. Diagnostic Pathology. 2016;11:5. doi:10.1186/s13000-016-0462-x.
- Gaujoux S., , Brennan, M., et al. Cystic Lesions of the Pancreas: Changes in the Presentation and Management of 1,424 Patients at a Single Institution over a 15-year Time Period. J Am Coll Surg. 2011 April; 212(4): doi:10.1016/j.jamcollsurg.2011.01.016.
- Kaimalkliotis, P., Riff, B., et al. Sendai and Fukuoka Consensus Guidelines Identify Advanced Neoplasia in Patients With Suspected Mucinous Cystic Neoplasms of the Pancreas. Clinical Gastroenterology and Hepatology 2015;13:1808–1815: doi:10.1016/j.cgh.2015.03.017
- Kushnir VM, Mullady DK, Das K, et al. J Clin Gastroenterol. 2019;53(9):686-692. DOI: 10.1097/MCG.0000000000001118.
- Gonda TA, Viterbo D, Gausman V, et al. Clin Gastroenterol Hepatol. 2017;15:913-919.